CD274 and non-small cell lung carcinoma: This findings led to the clinical development of antibodies blocking PD-1 or PD-L1, resulting in clinical responses in a variety of malignancies; such as melanomas, non-small cell lung carcinomas, and diffuse large B-cell lymphoma 11, 13.